Materials • Major Chemicals
$1.21 ▼ -0.01
(-0.82%)
MKT CAP: $299.2M • VOL: 1.86M
52W L $1 52W H $3
GEVO // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $160.6M | $16.9M | $17.2M |
| YoY Revenue Growth % | +849.3% | -1.7% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$20.2M | -$90.8M | -$81.8M |
| Operating Margin % | -12.6% | -80.0% | -80.0% |
| Net Income (GAAP) | -$33.8M | -$78.6M | -$66.2M |
| EBITDA (Normalized) | $3.9M | -$50.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$13.4M | -$57.4M | -$53.7M |
| Capital Expenditures (CapEx) | $30.1M | $51.1M | — |
| Free Cash Flow (FCF) | -$43.5M | -$108.5M | -$53.7M |
| FCF Margin % | -27.1% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -2.9% | -19.5% | — |
| Cash & Short-Term Equivalents | $81.2M | $189.4M | — |
| Total Debt (Short + Long Term) | $164.8M | $67.1M | — |
| Total Stockholders' Equity | $466.3M | $489.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR GEVO.